Shares of Esperion Therapeutics Inc (NASDAQ:ESPR) have received a consensus recommendation of “Buy” from the sixteen research firms that are currently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $77.23.
A number of equities analysts have recently weighed in on ESPR shares. Chardan Capital boosted their price objective on shares of Esperion Therapeutics from $20.00 to $75.00 and gave the company a “neutral” rating in a research report on Wednesday, December 6th. Needham & Company LLC raised shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and boosted their price objective for the company from $72.00 to $81.00 in a research report on Thursday, December 14th. UBS Group set a $88.00 price objective on shares of Esperion Therapeutics and gave the company a “buy” rating in a research report on Wednesday, January 17th. BidaskClub raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, December 16th. Finally, Northland Securities reissued a “buy” rating and issued a $72.00 price objective on shares of Esperion Therapeutics in a research report on Friday, November 10th.
In related news, Director Nicole Vitullo sold 9,326 shares of the company’s stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $53.85, for a total transaction of $502,205.10. Following the completion of the transaction, the director now owns 2,472 shares of the company’s stock, valued at $133,117.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 32.50% of the company’s stock.
Shares of Esperion Therapeutics (ESPR) traded up $1.81 during midday trading on Friday, hitting $74.88. 428,225 shares of the company’s stock traded hands, compared to its average volume of 595,517. Esperion Therapeutics has a 12 month low of $10.82 and a 12 month high of $82.18. The stock has a market capitalization of $1,970.00, a P/E ratio of -10.92 and a beta of 2.73.
Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.79) by ($0.07). During the same quarter in the prior year, the firm earned ($0.77) EPS. analysts predict that Esperion Therapeutics will post -7.3 earnings per share for the current year.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.